Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?
- 711 Downloads
Background and Objectives
Atrial fibrillation (AF) and the associated risk of stroke are emerging epidemics throughout the world. Suboptimal use of oral anticoagulants for stroke prevention has been widely reported from observational studies. In recent years, direct oral anticoagulants (DOACs) have been introduced for thromboprophylaxis. We conducted a systematic literature review to evaluate current practices of anticoagulation in AF, pharmacologic features and adoption patterns of DOACs, their impacts on proportion of eligible patients with AF who receive oral anticoagulants, persisting challenges and future prospects for optimal anticoagulation.
Literature Source and Selection Criteria
In conducting this review, we considered the results of relevant prospective and retrospective observational studies from real-world practice settings. PubMed (MEDLINE), Scopus (RIS), Google Scholar, EMBASE and Web of Science were used to source relevant literature. There were no date limitations, while language was limited to English. Selection was limited to articles from peer reviewed journals and related to our topic.
Most studies identified in this review indicated suboptimal use of anticoagulants is a persisting challenge despite the availability of DOACs. Underuse of oral anticoagulants is apparent particularly in patients with a high risk of stroke. DOAC adoption trends are quite variable, with slow integration into clinical practice reported in most countries; there has been limited impact to date on prescribing practice.
Available data from clinical practice suggest that suboptimal oral anticoagulant use in patients with AF and poor compliance with guidelines still remain commonplace despite transition to a new era of anticoagulation featuring DOACs.
KeywordsAtrial Fibrillation Warfarin International Normalize Ratio Dabigatran Rivaroxaban
Compliance with Ethics Guidelines
No external funding was used in the preparation of this manuscript.
Disclosure/conflict of interest
Endalkachew Admassie Alamneh has no conflicts of interest that might be relevant to the contents of this manuscript. Leanne Chalmers has received consultancy funding from Aspen Pharmacare Australia. Luke Bereznicki has received consultancy funding to research activities regarding anticoagulant medications from Roche Diagnostics, Boehringer Ingelheim and Aspen Pharmacare Australia. In 2015, he was a member of the Pradaxa Advisory Board in Australia.
- 10.January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–76.PubMedCrossRefGoogle Scholar
- 17.Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493–503.PubMedCrossRefGoogle Scholar
- 29.Lip GY, Andreotti F, Fauchier L, et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost. 2011;106(6):997–1011.PubMedCrossRefGoogle Scholar
- 34.National Clinical Guideline C. National Institute for Health and Clinical Excellence: Guidance. Atrial Fibrillation: The Management of Atrial Fibrillation. London: National Institute for Health and Care Excellence (UK), Copyright (c) National Clinical Guidelince Center; 2014.Google Scholar
- 35.Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–47.PubMedCrossRefGoogle Scholar
- 39.Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012;163(1):13–9.e1. doi: 10.1016/j.ahj.2011.09.011.
- 40.Huisman MV, Lip GY, Diener HC, et al. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. Am Heart J. 2014;167(3):329–34. doi: 10.1016/j.ahj.2013.12.006.PubMedCrossRefGoogle Scholar
- 42.Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events–European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014;16(1):6–14.PubMedPubMedCentralCrossRefGoogle Scholar
- 50.Ogilvie IM, Newton N, Welner SA. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638–45.e4.Google Scholar
- 51.Piyaskulkaew C, Singh T, Szpunar S, Saravolatz L 2nd, Rosman H. CHA(2)DS(2)-VASc versus CHADS(2) for stroke risk assessment in low-risk patients with atrial fibrillation: a pilot study from a single center of the NCDR-PINNACLE registry. J Thromb Thrombolysis. 2014;37(4):400–3. doi: 10.1007/s11239-013-0983-z.PubMedCrossRefGoogle Scholar
- 54.Lip GY, Laroche C, Dan GA, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace. 2014;16(3):308–19. doi: 10.1093/europace/eut373.PubMedCrossRefGoogle Scholar
- 59.Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010:ehq278.Google Scholar
- 67.Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015;4(1):e001486. doi: 10.1161/jaha.114.001486.PubMedPubMedCentralCrossRefGoogle Scholar
- 76.Haft JI. Stroke prevention in atrial fibrillation: impact of novel oral anticoagulants. Clin Applied Thromb Hemost. 2013;19(3):241–8.Google Scholar
- 82.Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.Google Scholar
- 85.Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160(4):635–41.PubMedCrossRefGoogle Scholar
- 89.Larsen TB, Gorst-Rasmussen A, Rasmussen LH, Skjoth F, Rosenzweig M, Lip GY. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med. 2014;127(7):650–6.e5.Google Scholar
- 93.Gonsalves WI, Pruthi RK, Patnaik MM, editors. The new oral anticoagulants in clinical practice. Mayo Clinic Proceedings: Elsevier; 2013.Google Scholar
- 96.Mohanty BD, Looser PM, Gokanapudy LR, et al. Controversies regarding the new oral anticoagulants for stroke prevention in patients with atrial fibrillation. Vasc Med (London, England). 2014;19(3):190–204. doi: 10.1177/1358863x14532869.
- 103.Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, et al. Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: the GLORIA-AF Registry, Phase II. Am J Med. 2015;128(12):1306–13.e1.Google Scholar
- 107.Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012;107(3):584–9. doi: 10.1160/th11-11-0784.PubMedCrossRefGoogle Scholar
- 108.Sorea C, Georger F, Makhoul R. 0203: analysis of antithrombotic therapy in patients over 75 years with non-valvular atrial fibrillation: do we apply the guidelines to elderly subjects? Arch Cardiovasc Dis Suppl. 2014;6:4.Google Scholar
- 110.Biskupiak J, Ghate S, Hamilton M, et al. Oral anticoagulant (OAC) utilization in atrial fibrillation after the introduction of novel oral anticoagulants. J Am Coll Cardiol. 2014;63(12_S). doi: 10.1016/S0735-1097(14)60326-0.
- 111.Shah N, Gosch K, Chan P, Marzec L, Ting H. Use of novel oral anticoagulants for patients with non-valvular atrial fibrillation: results from the NCDR PINNACLE registry. J Am Coll Cardiol. 2014;63(12_S). doi: 10.1016/S0735-1097(14)60332-6.
- 112.Gibbs H, Kakkar A. One year Australian outcome results of cohort 1 of the Global Anticoagulant Registry in the FIELD (GARFIELD) study. Heart, Lung Circ. 2013;22:S221-S.Google Scholar
- 113.Hamilton M, Kawabata H, Liu X, Brixner D, Biskupiak J. Utilization patterns of anticoagulants in non-valvular atrial fibrillation after the entry of novel oral anticoagulants in the United States. Circulation. 2012;126(21 Supplement):A9664.Google Scholar
- 118.Kakkar AK, Mueller I, Bassand JP, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One. 2013;8(5):e63479.PubMedPubMedCentralCrossRefGoogle Scholar
- 122.Granger CB, Armaganijan LV. Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. Circulation. 2012;125(1):159–64 (discussion 64).Google Scholar
- 123.Hernandez Olmedo M, Suarez Fernandez C. Progress of anticoagulation therapy in atrial fibrillation. Med Clin. 2014. doi: 10.1016/j.medcli.2014.07.018.